A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD

Overview

Journal Int J Chron Obstruct Pulmon Dis

Publisher Dove Medical Press

Specialty Pulmonary Medicine

Date 2020 Dec 4

PMID 33273812

Citations 1

Authors

Simon Wan Yau Ming

John Haughney

Dermot Ryan

Iain Small

Federico Lavorini

Alberto Papi

Dave Singh

David M G Halpin

John R Hurst

Shishir Patel

Matthias Ochel

Janwillem Kocks

Victoria Carter

Antony Hardjojo

David B Price

Affiliations

Soon will be listed here.

Abstract

Introduction: The Fostair® 100/6 (BDP/FF) pressurized metered-dose inhaler, delivering an extrafine formulation, is licensed for asthma and COPD in the UK. However, its real-life effectiveness for COPD has not been evaluated. This study compared the clinical effectiveness of BDP/FF against other licensed ICS/LABA combination inhalers: the Seretide® Accuhaler® (FP/SAL) and the Symbicort® Turbohaler® (BUD/FF).

Methods: A matched historical cohort study was conducted using records of patients with diagnostic codes for COPD from the Optimum Patient Care Research Database (OPCRD). Patients who had received BDP/FF as their first ICS/LABA were matched 1:1 with patients who had received FP/SAL or BUD/FF, resulting in two matched comparisons. Additional analysis was conducted on patients who had never had diagnostic codes for asthma. Noninferiority in terms of the proportion of patients with moderate/severe COPD exacerbations on the different inhalers in the following year was assessed. Noninferiority was achieved if the upper CI limit were ≤1.2.

Results: This study included 537 and 540 patient pairs in the BDP/FF vs FP/SAL cohort and the BDP/FF vs BUD/FF cohort, respectively. The proportion of patients with COPD exacerbations in the BDP/FF group was not significantly different from either the FP/SAL (68.7% vs 70.2%, AOR 0.89, 95% CI 0.67-1.19) or BUD/FF group (68.5% vs 69.4%, AOR 0.79, 95% CI 0.58-1.08). Noninferiority of BDP/FF in preventing COPD exacerbations was fulfilled in both comparisons. In patients without asthma, BDP/FF was also noninferior to BUD/FF (proportion with COPD exacerbations, 67.8% vs 64.7%, AOR 0.79, 95% CI 0.51-1.1997). Additionally, a significantly lower proportion of patients prescribed BDP/FF had COPD exacerbations than FP/SAL (64.8% vs 73.7%, AOR 0.64 95% CI 0.43-0.96).

Conclusion: Initiating ICS/LABA treatment of COPD with extrafine-formulation BDP/FF was noninferior in preventing moderate/severe exacerbations compared to FP/SAL and BUD/FF.

Citing Articles

Exacerbation history and blood eosinophil count prior to diagnosis of COPD and risk of subsequent exacerbations.

Halpin D, Healey H, Skinner D, Carter V, Pullen R, Price D Eur Respir J. 2024; 64(4).

PMID: 39147410 PMC: 11447287. DOI: 10.1183/13993003.02240-2023.

References

Roche N, Reddel H, Agusti A, Bateman E, Krishnan J, Martin R . Integrating real-life studies in the global therapeutic research framework. Lancet Respir Med. 2014; 1(10):e29-30. DOI: 10.1016/S2213-2600(13)70199-1. View

Price D, Chisholm A, Ryan D, Crockett A, Jones R . The use of roflumilast in COPD: a primary care perspective. Prim Care Respir J. 2010; 19(4):342-51. PMC: 6602268. DOI: 10.4104/pcrj.2010.00066. View

Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M . Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chron Obstruct Pulmon Dis. 2014; 9:889-904. PMC: 4154894. DOI: 10.2147/COPD.S62750. View

Nannini L, Poole P, Milan S, Kesterton A . Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013; (8):CD006826. PMC: 6486274. DOI: 10.1002/14651858.CD006826.pub2. View

Steiner J, Prochazka A . The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997; 50(1):105-16. DOI: 10.1016/s0895-4356(96)00268-5. View

Dekhuijzen P, Batsiou M, Bjermer L, Bosnic-Anticevich S, Chrystyn H, Papi A . Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: Effect of drug, dose, and device. Respir Med. 2016; 120:54-63. DOI: 10.1016/j.rmed.2016.09.015. View

Singh D, Nicolini G, Bindi E, Corradi M, Guastalla D, Kampschulte J . Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD. BMC Pulm Med. 2014; 14:43. PMC: 4008134. DOI: 10.1186/1471-2466-14-43. View

Price D, Small I, Haughney J, Ryan D, Gruffydd-Jones K, Lavorini F . Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. Prim Care Respir J. 2013; 22(4):439-48. PMC: 6443103. DOI: 10.4104/pcrj.2013.00088. View

Hagedorn C, Kassner F, Banik N, Ntampakas P, Fielder K . Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD. Respir Med. 2013; 107(4):542-9. DOI: 10.1016/j.rmed.2012.12.020. View

10.

Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K . Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014; 371(14):1285-94. DOI: 10.1056/NEJMoa1407154. View

11.

Covvey J, Mullen A, Ryan M, Steinke D, Johnston B, Wood F . A comparison of medication adherence/persistence for asthma and chronic obstructive pulmonary disease in the United Kingdom. Int J Clin Pract. 2014; 68(10):1200-8. DOI: 10.1111/ijcp.12451. View

12.

Haughney J, Price D, Barnes N, Virchow J, Roche N, Chrystyn H . Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med. 2010; 104(9):1237-45. DOI: 10.1016/j.rmed.2010.04.012. View

13.

Calverley P, Kuna P, Monso E, Costantini M, Petruzzelli S, Sergio F . Beclomethasone/formoterol in the management of COPD: a randomised controlled trial. Respir Med. 2010; 104(12):1858-68. DOI: 10.1016/j.rmed.2010.09.008. View

14.

Scichilone N, Benfante A, Morandi L, Bellini F, Papi A . Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD. Patient Relat Outcome Meas. 2014; 5:153-62. PMC: 4251568. DOI: 10.2147/PROM.S55276. View

15.

Molimard M, Raherison C, Lignot S, Balestra A, Lamarque S, Chartier A . Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017; 49(2). DOI: 10.1183/13993003.01794-2016. View

16.

Scichilone N, Battaglia S, Sorino C, Paglino G, Martino L, Paterno A . Effects of extra-fine inhaled beclomethasone/formoterol on both large and small airways in asthma. Allergy. 2010; 65(7):897-902. DOI: 10.1111/j.1398-9995.2009.02306.x. View

17.

Price D, Yawn B, Brusselle G, Rossi A . Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J. 2012; 22(1):92-100. PMC: 6548052. DOI: 10.4104/pcrj.2012.00092. View

18.

Montuschi P, Malerba M, Santini G, Miravitlles M . Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. Drug Discov Today. 2014; 19(12):1928-35. DOI: 10.1016/j.drudis.2014.08.004. View

19.

Melani A, Bonavia M, Cilenti V, Cinti C, Lodi M, Martucci P . Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011; 105(6):930-8. DOI: 10.1016/j.rmed.2011.01.005. View

20.

Singh D, Vezzoli S, Petruzzelli S, Papi A . The efficacy of extrafine beclomethasone dipropionate-formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study. Int J Chron Obstruct Pulmon Dis. 2017; 12:3263-3271. PMC: 5680966. DOI: 10.2147/COPD.S141416. View